Guanabenz: Clinical Trials

4 trials of Guanabenz, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 completed, 1 unknown. 1 Not applicable, 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Not applicable1Terminated 1
Phase 11Terminated 1
Phase 21Unknown 1

Follow Guanabenz: new trials by email Literature Review of Guanabenz trials Research Report on Guanabenz

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease
Experimental: 4 mg/day of WY-8678 (guanabenz acetate), Experimental: 8 mg/day of WY-8678 (guanabenz acetate) - Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Phase 2UnknownYokohama City University292021-10-292022-09-27
ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
ACEI/ARB, Non-ACEI/ARB, ACEI - Hypertension, COVID
CompletedUniversity of Utah222132020-01-192021-04-28
Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
Guanabenz acetate - Bone Cancer, Metastasis
Not applicableTerminatedKathy Miller42015-05-072018-02-13
Oral Guanabenz for Multiple Sclerosis
Guanabenz - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis
Phase 1TerminatedNational Institute of Neurological Disorders and Stroke (NINDS)22015-04-212019-12-12

Conditions studied

Bone Neoplasms (1)  ·  Hypertension (1)  ·  Multiple Sclerosis (1)  ·  Multiple Sclerosis, Relapsing-Remitting (1)  ·  Neoplasm Metastasis (1)  ·  Non-alcoholic Fatty Liver Disease (1)

Sponsors

Kathy Miller (1)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (1)  ·  University of Utah (1)  ·  Yokohama City University (1)

Countries

United States (3)  ·  Japan (1)

Top investigators

Adam P Bress, PharmD, MS (1)  ·  Irene CM Cortese, M.D. (1)  ·  Kathy Miller, MD (1)

Results publications

PMID 27055915, PMID 33891615, PMID 35820743